Avalo Therapeutics
June 18, 2025
Company Presentation
Immunology
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases- a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. Avalo is currently studying AVTX-009 in a Phase 2 trial in patients with hidradenitis suppurativa, a chronic, often debilitating, inflammatory skin disease. Topline data from the LOTUS study is expected in 2026.
Company HQ City:
Wayne
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2011
Lead Product in Development:
AVTX-009
CEO
Garry Neil, MD
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
Exchange
Nasdaq Capital Market
Ticker
AVTX
When you expect your next catalyst update?
LOTUS Trial Readout
What is your next catalyst (value inflection) update?
2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}